Comparison of Infliximab and Adalimumab in Biologic-Naive Patients With Ulcerative Colitis: A Nationwide Danish Cohort Study.

ABSTRACT:

Background & aims

This study compares the effectiveness and safety of infliximab and adalimumab in biologic-naive patients with ulcerative colitis (UC), in a nationwide register-based propensity score-matched cohort study.

Methods

From 1719 adults with UC, between ages 15 and 75 years in Denmark treated with either infliximab or adalimumab as their first biologic agent, we compared rates of all-cause hospitalization, UC-related hospitalization, major abdominal surgery, and serious infections after a variable 2:1 propensity score matching, accounting for baseline clinical characteristics, disease severity, health care utilization, and use of UC-related medications.

Results

As compared with infliximab-treated patients, adalimumab-treated patients had higher rate of all-

SUBMITTER: Singh S 

PROVIDER: S-EPMC5447492 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature